Literature DB >> 25814628

Nasal Inoculation of the Commensal Neisseria lactamica Inhibits Carriage of Neisseria meningitidis by Young Adults: A Controlled Human Infection Study.

Alice M Deasy1, Ed Guccione1, Adam P Dale2, Nick Andrews3, Cariad M Evans1, Julia S Bennett4, Holly B Bratcher4, Martin C J Maiden4, Andrew R Gorringe5, Robert C Read2.   

Abstract

BACKGROUND: Herd protection by meningococcal vaccines is conferred by population-level reduction of meningococcal nasopharyngeal colonization. Given the inverse epidemiological association between colonization by commensal Neisseria lactamica and meningococcal disease, we investigated whether controlled infection of human volunteers with N. lactamica prevents colonization by Neisseria meningitidis.
METHODS: In a block-randomized human challenge study, 310 university students were inoculated with 10(4) colony-forming units of N. lactamica or were sham-inoculated, and carriage was monitored for 26 weeks, after which all participants were reinoculated with N. lactamica and resampled 2 weeks later.
RESULTS: At baseline, natural N. meningitidis carriage in the control group was 22.4% (36/161), which increased to 33.6% (48/143) by week 26. Two weeks after inoculation of N. lactamica, 33.6% (48/143) of the challenge group became colonized with N. lactamica. In this group, meningococcal carriage reduced from 24.2% (36/149) at inoculation to 14.7% (21/143) 2 weeks after inoculation (-9.5%; P = .006). The inhibition of meningococcal carriage was only observed in carriers of N. lactamica, was due both to displacement of existing meningococci and to inhibition of new acquisition, and persisted over at least 16 weeks. Crossover inoculation of controls with N. lactamica replicated the result. Genome sequencing showed that inhibition affected multiple meningococcal sequence types.
CONCLUSIONS: The inhibition of meningococcal carriage by N. lactamica is even more potent than after glycoconjugate meningococcal vaccination. Neisseria lactamica or its components could be a novel bacterial medicine to suppress meningococcal outbreaks. This observation explains the epidemiological observation of natural immunity conferred by carriage of N. lactamica. CLINICAL TRIALS REGISTRATION: NCT02249598.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Neisseria lactamica; Neisseria meningitidis; herd protection; meningococcal carriage; meningococcal vaccination

Mesh:

Year:  2015        PMID: 25814628     DOI: 10.1093/cid/civ098

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  44 in total

1.  Neisseria meningitidis Serogroup X ST-5799 (ST-22 complex) in Turkey: A unique pediatric case.

Authors:  Gönül Tanır; Yasemin Ozsurekci; Jay Lucidarme; Sevgi Yaşar Durmuş; Aiswarya Lekshmi; Özlem Akisoglu; Ahmet Emre Aycan; Ray Borrow; Mehmet Ceyhan
Journal:  Hum Vaccin Immunother       Date:  2017-12-11       Impact factor: 3.452

Review 2.  Et tu, Neisseria? Conflicts of Interest Between Neisseria Species.

Authors:  Rene Baerentsen; Christoph M Tang; Rachel M Exley
Journal:  Front Cell Infect Microbiol       Date:  2022-06-24       Impact factor: 6.073

3.  Commensal Neisseria Kill Neisseria gonorrhoeae through a DNA-Dependent Mechanism.

Authors:  Won Jong Kim; Dustin Higashi; Maira Goytia; Maria A Rendón; Michelle Pilligua-Lucas; Matthew Bronnimann; Jeanine A McLean; Joseph Duncan; David Trees; Ann E Jerse; Magdalene So
Journal:  Cell Host Microbe       Date:  2019-08-01       Impact factor: 21.023

4.  Limited Impact of Adolescent Meningococcal ACWY Vaccination on Neisseria meningitidis Serogroup W Carriage in University Students.

Authors:  Neil J Oldfield; Luke R Green; Julian Parkhill; Christopher D Bayliss; David P J Turner
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

Review 5.  Commensal bacteria in the upper respiratory tract regulate susceptibility to infection.

Authors:  Sarah E Clark
Journal:  Curr Opin Immunol       Date:  2020-05-19       Impact factor: 7.486

6.  Pharyngeal carriage of Neisseria species in the African meningitis belt.

Authors:  Kanny Diallo; Caroline Trotter; Youssouf Timbine; Boubou Tamboura; Samba O Sow; Bassira Issaka; Ibrahim D Dano; Jean-Marc Collard; Marietou Dieng; Aldiouma Diallo; Adane Mihret; Oumer A Ali; Abraham Aseffa; Stephen L Quaye; Akalifa Bugri; Isaac Osei; Kadidja Gamougam; Lodoum Mbainadji; Doumagoum M Daugla; Galadima Gadzama; Zailani B Sambo; Babatunji A Omotara; Julia S Bennett; Lisa S Rebbetts; Eleanor R Watkins; Maria Nascimento; Arouna Woukeu; Olivier Manigart; Ray Borrow; James M Stuart; Brian M Greenwood; Martin C J Maiden
Journal:  J Infect       Date:  2016-03-23       Impact factor: 6.072

7.  Prevalence and epidemiology of meningococcal carriage in Southern Ethiopia prior to implementation of MenAfriVac, a conjugate vaccine.

Authors:  Guro K Bårnes; Paul A Kristiansen; Demissew Beyene; Bereket Workalemahu; Paulos Fissiha; Behailu Merdekios; Jon Bohlin; Marie-Pierre Préziosi; Abraham Aseffa; Dominique A Caugant
Journal:  BMC Infect Dis       Date:  2016-11-04       Impact factor: 3.090

8.  Neisseria cinerea isolates can adhere to human epithelial cells by type IV pilus-independent mechanisms.

Authors:  Mirka E Wörmann; Corey L Horien; Errin Johnson; Guangyu Liu; Ellen Aho; Christoph M Tang; Rachel M Exley
Journal:  Microbiology (Reading)       Date:  2016-01-26       Impact factor: 2.777

9.  Colistin Sensitivity and Factor H-Binding Protein Expression among Commensal Neisseria Species.

Authors:  Stephen A Clark; Steve Gray; Adam Finn; Ray Borrow
Journal:  mSphere       Date:  2021-06-16       Impact factor: 4.389

10.  Type VI secretion system killing by commensal Neisseria is influenced by expression of type four pili.

Authors:  Rafael Custodio; Rhian M Ford; Cara J Ellison; Guangyu Liu; Gerda Mickute; Christoph M Tang; Rachel M Exley
Journal:  Elife       Date:  2021-07-07       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.